Skip to content

Study on suppression of blood glucose elevation by consumption of research foods (preliminary test) 3 groups.

Study on suppression of blood glucose elevation by consumption of research foods (preliminary test) 3 groups. - Study on suppression of blood glucose elevation by consumption of research foods (preliminary test) 3 groups.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000045463
Enrollment
9
Registered
2021-09-17
Start date
2021-09-21
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adult male

Interventions

1 grains of the test product daily oral intake for 4 weeks. 2 grains of the test product daily oral intake for 4 weeks. 4 grains of the test product daily oral intake for 4 weeks.

Sponsors

EP Mediate Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: Male between 20 and 64 years of age.

Exclusion criteria

Exclusion criteria: (1) Subjects who regularly use functional foods or supplements containing omega-3 fatty acids such as DHA, EPA, and Alpha-linolenic acid. (2) Subjects who regularly use functional foods or supplements containing algae (e.g., aurantiochytrium, euglena, spirulina, greenbug, etc.) (3) Subjects who regularly use medicines, health foods, foods for specified health uses, or functional foods that may affect blood glucose metabolism. (4) Subjects who are under treatment or have a history of serious diseases (e.g., diabetes, liver disease, kidney disease, or heart disease). (5) Subjects who have a disease under treatment, or a serious or pre-existing disease that requires medication. (6) Subjects with diseases that may cause diabetes or abnormalities in glucose metabolism, and subjects with a history of such diseases (e.g., pancreatic diseases, endocrine disorders, gastrectomy) (7) Subjects having possibilities for emerging allergy related to the study. (8) Subjects who are judged as unsuitable for the study based on the results of clinical and physical examination before intake. (9) Subjects who have participated in other clinical study within the last one month prior to the current study or are planned to participate in other clinical study after informed consent for the current study. (10) Subjects who are judged as unsuitable for the study based on the results of lifestyle questionnaire and other questionnaires. (11) Subjects who have donated of blood within 1 month before beginning pre-inspection. (12) Subjects who are judged as unsuitable for the study by the investigator for other reason.

Design outcomes

Primary

MeasureTime frame
Area under the curve of blood glucose level (AUC), Area under the rising curve of blood glucose level (IAUC) Evaluate at points of 4 week of intake period.

Secondary

MeasureTime frame
Area under the curve of insulin level (AUC), Area under the rising curve of insulin level (IAUC), insulinogenic index, Fasting blood glucose level, HbA1c Evaluate at points of 4 week of intake period.

Countries

Japan

Contacts

Public ContactMasahiro Ikeda

EP Mediate Co., Ltd. Development Business Headquarters, TTC Center, Trial Planning Department

ikeda.masahiro083@eps.co.jp090-4964-4061

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026